Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734604 · ClinicalTrials.gov registry record · Phase 3
A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 378
- Enrollment target
NCT00734604 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 378 participants.
The verdict
NCT00734604, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 378 participants
- Enrollment target
Study Summary
The primary purpose of the study is to help answer whether tadalafil taken once a day can help improve the psychological outcomes (such as sexual self confidence, spontaneity and time concerns) compared to sildenafil taken as needed in patients with erectile dysfunction (ED).
Interventions
- DRUG tadalafil once a day [T(OaD)]
- DRUG sildenafil citrate as needed [S(PRN)]
- DRUG tadalafil as needed [T(PRN)]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 378 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00734604
The ClinicalTrials.gov registry entry for NCT00734604 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 378 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which tadalafil once a day [T(OaD)] is the first listed.
NCT00734604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00734604 about?
NCT00734604 is a clinical study titled "A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.". The primary purpose of the study is to help answer whether tadalafil taken once a day can help improve the psychological outcomes (such as sexual self confidence, spontaneity and time concerns) compared to sildenafil taken as needed in patients with erectile dysfunction (ED).
What is the current status of trial NCT00734604?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 378 participants. The study started on 2008-08. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00734604?
The interventions under investigation include: tadalafil once a day [T(OaD)] (DRUG), sildenafil citrate as needed [S(PRN)] (DRUG), tadalafil as needed [T(PRN)] (DRUG).
Who is sponsoring clinical trial NCT00734604?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.